Cited 9 times in
An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 석정호 | - |
dc.date.accessioned | 2014-12-18T09:48:12Z | - |
dc.date.available | 2014-12-18T09:48:12Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0176-3679 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88859 | - |
dc.description.abstract | The present study aimed at investigating the effectiveness and tolerability of -bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF).51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment.The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%).Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | PHARMACOPSYCHIATRY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antidepressive Agents, Second-Generation/administration & dosage | - |
dc.subject.MESH | Antidepressive Agents, Second-Generation/adverse effects | - |
dc.subject.MESH | Antidepressive Agents, Second-Generation/therapeutic use* | - |
dc.subject.MESH | Bupropion/administration & dosage | - |
dc.subject.MESH | Bupropion/adverse effects | - |
dc.subject.MESH | Bupropion/therapeutic use* | - |
dc.subject.MESH | Delayed-Action Preparations/adverse effects | - |
dc.subject.MESH | Depressive Disorder, Major/diagnosis | - |
dc.subject.MESH | Depressive Disorder, Major/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Psychiatric Status Rating Scales | - |
dc.subject.MESH | Single-Blind Method | - |
dc.title | An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Psychiatry (정신과학) | - |
dc.contributor.googleauthor | H.-J. Seo | - |
dc.contributor.googleauthor | B. C. Lee | - |
dc.contributor.googleauthor | J.-H. Seok | - |
dc.contributor.googleauthor | H. J. Jeon | - |
dc.contributor.googleauthor | J.-W. Paik | - |
dc.contributor.googleauthor | W. Kim | - |
dc.contributor.googleauthor | K.-P. Kwak | - |
dc.contributor.googleauthor | C. Han | - |
dc.contributor.googleauthor | K.-U. Lee | - |
dc.contributor.googleauthor | C.-U. Pae | - |
dc.identifier.doi | 10.1055/s-0033-1353171 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01929 | - |
dc.relation.journalcode | J02512 | - |
dc.identifier.eissn | 1439-0795 | - |
dc.identifier.pmid | 23963965 | - |
dc.identifier.url | https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0033-1353171 | - |
dc.subject.keyword | bupropion XL | - |
dc.subject.keyword | atypical depression | - |
dc.subject.keyword | effectiveness | - |
dc.subject.keyword | remission | - |
dc.subject.keyword | response | - |
dc.subject.keyword | tolerability | - |
dc.contributor.alternativeName | Seok, Jeong Ho | - |
dc.contributor.affiliatedAuthor | Seok, Jeong Ho | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 46 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 221 | - |
dc.citation.endPage | 226 | - |
dc.identifier.bibliographicCitation | PHARMACOPSYCHIATRY, Vol.46(6) : 221-226, 2013 | - |
dc.identifier.rimsid | 33670 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.